File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma

TitleAdoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma
Authors
KeywordsAdoptive immune transfer
Cytotoxic T cell
Epstein-Barr virus
Nasopharyngeal carcinoma
Peripheral blood monocyte
Issue Date2001
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2001, v. 94 n. 1, p. 73-80 How to Cite?
AbstractTumor cells from NPC patients are regularly and latently infected with EBV. To examine whether the virus serves as target for immune intervention of the cancer, we determined levels of EBV-specific CTLp in peripheral blood from NPC patients, long-term survivors of the cancer and healthy subjects. CTLp levels of test subjects varied between 3-3,000/10 6 PBMCs. The plasma EBV burden increased when the CTLp level fell below 150, whereas the EBV burden of PBMCs was not correlated with CTLp level. Compared with healthy carriers, CTLp levels of patients were lower and varied over a wider range, between 3-1,500/10 6 PBMCs. The quantitative immune deficit was probably attributed to the tumor because, first, CTLp in survivors was restored to levels similar to those in healthy carriers after the tumor had been successfully treated. Second, the CTLp level changed as disease progressed, being lower in local disease, increased in locoregional disease and decreased again when the tumor metastasized. Based on these findings, 4 patients with advanced disease were infused with 5 × 10 7 - 3 × 10 8 autologous EBV CTLs. The treatment was safe and unaccompanied by inflammatory or other complications, but whether it improved tumor control could not be discerned from the large tumor bulk. Nevertheless, the treatment regularly increased CTLp levels of patients, maintained it at higher levels for protracted periods and, in 3 patients, restored host surveillance of EBV replication, reducing the plasma EBV burden. Taken together, these results provided a rationale to further explore EBV as a target of immune intervention of NPC. © 2001 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/71920
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChua, Den_HK
dc.contributor.authorHuang, Jen_HK
dc.contributor.authorZheng, Ben_HK
dc.contributor.authorLau, SYen_HK
dc.contributor.authorLuk, Wen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorMoss, Den_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorIm, SWKen_HK
dc.contributor.authorNg, MHen_HK
dc.date.accessioned2010-09-06T06:36:30Z-
dc.date.available2010-09-06T06:36:30Z-
dc.date.issued2001en_HK
dc.identifier.citationInternational Journal Of Cancer, 2001, v. 94 n. 1, p. 73-80en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71920-
dc.description.abstractTumor cells from NPC patients are regularly and latently infected with EBV. To examine whether the virus serves as target for immune intervention of the cancer, we determined levels of EBV-specific CTLp in peripheral blood from NPC patients, long-term survivors of the cancer and healthy subjects. CTLp levels of test subjects varied between 3-3,000/10 6 PBMCs. The plasma EBV burden increased when the CTLp level fell below 150, whereas the EBV burden of PBMCs was not correlated with CTLp level. Compared with healthy carriers, CTLp levels of patients were lower and varied over a wider range, between 3-1,500/10 6 PBMCs. The quantitative immune deficit was probably attributed to the tumor because, first, CTLp in survivors was restored to levels similar to those in healthy carriers after the tumor had been successfully treated. Second, the CTLp level changed as disease progressed, being lower in local disease, increased in locoregional disease and decreased again when the tumor metastasized. Based on these findings, 4 patients with advanced disease were infused with 5 × 10 7 - 3 × 10 8 autologous EBV CTLs. The treatment was safe and unaccompanied by inflammatory or other complications, but whether it improved tumor control could not be discerned from the large tumor bulk. Nevertheless, the treatment regularly increased CTLp levels of patients, maintained it at higher levels for protracted periods and, in 3 patients, restored host surveillance of EBV replication, reducing the plasma EBV burden. Taken together, these results provided a rationale to further explore EBV as a target of immune intervention of NPC. © 2001 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectAdoptive immune transferen_HK
dc.subjectCytotoxic T cellen_HK
dc.subjectEpstein-Barr virusen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPeripheral blood monocyteen_HK
dc.subject.meshAdoptive Transferen_HK
dc.subject.meshAdulten_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHematopoietic Stem Cells - immunologyen_HK
dc.subject.meshHerpesvirus 4, Human - immunologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNasopharyngeal Neoplasms - immunology - therapy - virologyen_HK
dc.subject.meshT-Lymphocytes, Cytotoxic - immunologyen_HK
dc.subject.meshTumor Cells, Cultureden_HK
dc.titleAdoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=94&issue=1&spage=73&epage=80&date=2001&atitle=Adoptive+transfer+of+autologous+Epstein-Barr+virus-specific+cytotoxic+T+cells+for+nasopharyngeal+carcinomaen_HK
dc.identifier.emailChua, D: dttchua@hkucc.hku.hken_HK
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityChua, D=rp00415en_HK
dc.identifier.authorityZheng, B=rp00353en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ijc.1430en_HK
dc.identifier.pmid11668481-
dc.identifier.scopuseid_2-s2.0-17944381522en_HK
dc.identifier.hkuros69686en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-17944381522&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume94en_HK
dc.identifier.issue1en_HK
dc.identifier.spage73en_HK
dc.identifier.epage80en_HK
dc.identifier.isiWOS:000170752600011-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChua, D=7006773480en_HK
dc.identifier.scopusauthoridHuang, J=7407189939en_HK
dc.identifier.scopusauthoridZheng, B=7201780588en_HK
dc.identifier.scopusauthoridLau, SY=7401596375en_HK
dc.identifier.scopusauthoridLuk, W=7005237837en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridSham, JST=7101655565en_HK
dc.identifier.scopusauthoridMoss, D=7201847881en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridIm, SWK=22943859000en_HK
dc.identifier.scopusauthoridNg, MH=7202076421en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats